| __timestamp | Johnson & Johnson | Pfizer Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 21954000000 | 14097000000 |
| Thursday, January 1, 2015 | 21203000000 | 14809000000 |
| Friday, January 1, 2016 | 19945000000 | 14837000000 |
| Sunday, January 1, 2017 | 21420000000 | 14784000000 |
| Monday, January 1, 2018 | 22540000000 | 14455000000 |
| Tuesday, January 1, 2019 | 22178000000 | 14350000000 |
| Wednesday, January 1, 2020 | 22084000000 | 11615000000 |
| Friday, January 1, 2021 | 20118000000 | 12703000000 |
| Saturday, January 1, 2022 | 19046000000 | 13677000000 |
| Sunday, January 1, 2023 | 20112000000 | 14771000000 |
| Monday, January 1, 2024 | 21969000000 | 14730000000 |
Cracking the code
In the ever-evolving pharmaceutical industry, understanding the financial strategies of giants like Johnson & Johnson and Pfizer Inc. is crucial. Over the past decade, from 2014 to 2023, these companies have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. Johnson & Johnson's SG&A expenses peaked in 2018, reaching approximately 10% higher than their 2022 figures, indicating a strategic shift or cost optimization. Meanwhile, Pfizer Inc. maintained a relatively stable SG&A expenditure, with a slight dip in 2020, possibly reflecting pandemic-related adjustments. By 2023, Pfizer's expenses rebounded to levels similar to 2015, showcasing resilience and adaptability. This comparative analysis not only highlights the financial discipline of these industry leaders but also offers insights into their operational priorities and market strategies.
Cost Management Insights: SG&A Expenses for Johnson & Johnson and AstraZeneca PLC
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Selling, General, and Administrative Costs: Johnson & Johnson vs Gilead Sciences, Inc.
Comparing SG&A Expenses: Johnson & Johnson vs Bausch Health Companies Inc. Trends and Insights
Breaking Down SG&A Expenses: Johnson & Johnson vs Galapagos NV
Selling, General, and Administrative Costs: Pfizer Inc. vs Vertex Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: Pfizer Inc. vs GSK plc
Who Optimizes SG&A Costs Better? Pfizer Inc. or Pharming Group N.V.
SG&A Efficiency Analysis: Comparing Pfizer Inc. and Rhythm Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Pfizer Inc. or Catalyst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Pfizer Inc. vs Mesoblast Limited
Breaking Down SG&A Expenses: Pfizer Inc. vs Dynavax Technologies Corporation